[go: up one dir, main page]

ZA200108856B - Treatment of neurotic disorders. - Google Patents

Treatment of neurotic disorders.

Info

Publication number
ZA200108856B
ZA200108856B ZA200108856A ZA200108856A ZA200108856B ZA 200108856 B ZA200108856 B ZA 200108856B ZA 200108856 A ZA200108856 A ZA 200108856A ZA 200108856 A ZA200108856 A ZA 200108856A ZA 200108856 B ZA200108856 B ZA 200108856B
Authority
ZA
South Africa
Prior art keywords
treatment
neurotic disorders
neurotic
disorders
Prior art date
Application number
ZA200108856A
Other languages
English (en)
Inventor
Connie Sanchez
Sandra Hogg
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200108856(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA200108856B publication Critical patent/ZA200108856B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200108856A 1999-07-08 2001-10-26 Treatment of neurotic disorders. ZA200108856B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08

Publications (1)

Publication Number Publication Date
ZA200108856B true ZA200108856B (en) 2002-12-24

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108856A ZA200108856B (en) 1999-07-08 2001-10-26 Treatment of neurotic disorders.

Country Status (38)

Country Link
US (6) US7271194B2 (xx)
EP (4) EP1440689A3 (xx)
JP (1) JP4773011B2 (xx)
KR (1) KR100604176B1 (xx)
CN (1) CN1198610C (xx)
AR (1) AR021155A1 (xx)
AT (1) ATE339955T1 (xx)
AU (6) AU782514B2 (xx)
BG (4) BG110466A (xx)
BR (1) BR0011578A (xx)
CA (4) CA2373757C (xx)
CL (3) CL2008003941A1 (xx)
CO (1) CO5190674A1 (xx)
CY (1) CY1105806T1 (xx)
CZ (1) CZ200270A3 (xx)
DE (1) DE60030861T2 (xx)
DK (1) DK1200081T3 (xx)
EA (1) EA006555B1 (xx)
ES (1) ES2272298T3 (xx)
HK (1) HK1048069B (xx)
HR (1) HRP20010820A2 (xx)
HU (1) HUP0201791A3 (xx)
IL (5) IL146131A0 (xx)
IS (1) IS6137A (xx)
ME (2) ME00032B (xx)
MX (1) MXPA01011626A (xx)
MY (1) MY143278A (xx)
NO (4) NO329021B1 (xx)
PL (1) PL352030A1 (xx)
PT (1) PT1200081E (xx)
SI (1) SI1200081T1 (xx)
SK (1) SK82002A3 (xx)
TR (4) TR200200014T2 (xx)
TW (1) TWI232101B (xx)
UA (1) UA77645C2 (xx)
WO (1) WO2001003694A1 (xx)
YU (1) YU78701A (xx)
ZA (1) ZA200108856B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
EA005621B1 (ru) 2000-07-21 2005-04-28 Х.Лундбекк А/С Гетероциклические соединения в качестве ингибиторов транспортера глицина
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama
DK1522539T3 (da) 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
US20040067963A1 (en) * 2002-07-08 2004-04-08 University Of Florida Methods to prevent or ameliorate trauma-related psychological disorders
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (en) * 2003-12-02 2010-04-21 PharmaNeuroBoost N.V. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
AU2006308635A1 (en) 2005-10-14 2007-05-10 H. Lundbeck A/S Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (xx) * 1965-03-18
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4436874A (en) 1981-11-19 1984-03-13 Societe D'expansion Scientifique "Expansia" Acrylic copolymers and their use in solid phase peptide synthesis
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO1993009769A1 (en) 1991-11-15 1993-05-27 Sepracor, Inc. Methods and compositions utilizing pure s(+) isomer fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
AU6776196A (en) 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
CZ292911B6 (cs) * 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
ES2188095T3 (es) * 1998-04-15 2003-06-16 Pfizer Prod Inc Carboxamidas heterociclicas.
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
NZ510858A (en) * 1998-10-20 2003-11-28 H Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama

Also Published As

Publication number Publication date
BR0011578A (pt) 2002-03-26
CA2373757C (en) 2010-01-05
AU782514B2 (en) 2005-08-04
CL2008003941A1 (es) 2009-05-22
US7265151B2 (en) 2007-09-04
NO20100333L (no) 2002-01-07
AU2005202684B2 (en) 2009-01-15
EP1440691A3 (en) 2004-08-25
PT1200081E (pt) 2007-01-31
TR200200014T2 (tr) 2002-05-21
DE60030861D1 (de) 2006-11-02
EA200200137A1 (ru) 2002-06-27
CL2008003939A1 (es) 2009-06-05
YU78701A (sh) 2004-03-12
UA77645C2 (en) 2007-01-15
ES2272298T3 (es) 2007-05-01
BG110466A (en) 2010-01-29
IL170193A (en) 2010-04-29
AU2008264182A1 (en) 2009-01-29
US20040029956A1 (en) 2004-02-12
CA2373757A1 (en) 2001-01-18
TR200402276T2 (tr) 2005-01-24
US7271194B2 (en) 2007-09-18
MY143278A (en) 2011-04-15
EP1440690A3 (en) 2004-08-18
DK1200081T3 (da) 2006-12-27
JP4773011B2 (ja) 2011-09-14
US20020086899A1 (en) 2002-07-04
AU2008264188A1 (en) 2009-05-07
AU5806100A (en) 2001-01-30
EP1440689A3 (en) 2004-08-25
BG110467A (en) 2010-01-29
CZ200270A3 (cs) 2002-04-17
MXPA01011626A (es) 2002-06-04
SK82002A3 (en) 2002-07-02
CL2008003938A1 (es) 2009-05-22
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
HRP20010820A2 (en) 2003-08-31
NO20100335L (no) 2002-01-07
AU2005202685A1 (en) 2005-07-14
IL146131A (en) 2007-02-11
ATE339955T1 (de) 2006-10-15
ME00032B (me) 2010-02-10
PL352030A1 (en) 2003-07-28
EP1200081A1 (en) 2002-05-02
CO5190674A1 (es) 2002-08-29
TR200402275T2 (tr) 2005-03-21
TR200402277T2 (tr) 2005-01-24
EP1440689A2 (en) 2004-07-28
US6960613B2 (en) 2005-11-01
CA2687394A1 (en) 2001-01-18
AU2005202686B2 (en) 2009-01-15
AR021155A1 (es) 2002-06-12
NO20020062D0 (no) 2002-01-07
EA006555B1 (ru) 2006-02-24
AU2005202686A1 (en) 2005-07-14
WO2001003694A1 (en) 2001-01-18
EP1440690A2 (en) 2004-07-28
US20040029957A1 (en) 2004-02-12
US20070276035A1 (en) 2007-11-29
HUP0201791A3 (en) 2005-02-28
AU2005202685B2 (en) 2009-01-15
CY1105806T1 (el) 2011-02-02
CA2687396A1 (en) 2001-01-18
EP1200081B1 (en) 2006-09-20
HUP0201791A2 (en) 2002-10-28
IL170194A (en) 2010-05-31
HK1048069A1 (en) 2003-03-21
NO20100334L (no) 2002-01-07
CA2687392A1 (en) 2001-01-18
KR20020015346A (ko) 2002-02-27
DE60030861T2 (de) 2007-05-03
KR100604176B1 (ko) 2006-07-25
CN1360501A (zh) 2002-07-24
BG106279A (bg) 2002-08-30
MEP2508A (xx) 2010-02-10
AU2005202684A1 (en) 2005-07-14
EP1440691A2 (en) 2004-07-28
HK1048069B (zh) 2005-12-16
NO329021B1 (no) 2010-07-26
US20050101665A1 (en) 2005-05-12
IL146131A0 (en) 2002-07-25
US20040029958A1 (en) 2004-02-12
IS6137A (is) 2001-10-30
IL170192A (en) 2010-04-29
CN1198610C (zh) 2005-04-27
JP2003504332A (ja) 2003-02-04
BG110468A (en) 2010-01-29
TWI232101B (en) 2005-05-11

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
ZA200108856B (en) Treatment of neurotic disorders.
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
ZA200105690B (en) Novel treatment.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB9926968D0 (en) Treatment of neurological disorders
AU7106300A (en) Treatment of skin disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
CZ20011872A3 (cs) Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
GB0010496D0 (en) Treatment of conditions of the central nervous system
AU3582101A (en) The treatment of functional gastrointestinal disorders
GB9924942D0 (en) Treatment of movement disorders
HUP0301798A3 (en) Treatment of eating disorders using carboxyalkylethers
GB0017951D0 (en) Treatment of movement disorders
GB0003228D0 (en) Treatment of GI disorders
ZA200202842B (en) Skin treatment compositions.
GB0004998D0 (en) The treatment of functional gastrointestinal disorders
GB9815188D0 (en) Treatment of skin disorders
GB9919126D0 (en) Glaucoma treatment
GB9925550D0 (en) Glaucoma treatment
GB9923551D0 (en) Treatment of neuropsychiatric disorders
GB0021060D0 (en) Treatment of functional gastrointestinal disorders